MentionFox
Home › Executive changes › Pasithea Therapeutics Corp.
Leadership changes · KTTA · SEC Form 8-K, Item 5.02

Leadership changes at Pasithea Therapeutics Corp. (2026)

Before you join, sell to or invest in Pasithea Therapeutics Corp.

MentionFox check on Pasithea Therapeutics Corp.: only 1 source on file so far (checked 15 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/pasithea-therapeutics

Check Pasithea Therapeutics Corp. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Pasithea Therapeutics Corp.?

Who joined and who left Pasithea Therapeutics Corp. (KTTA)? 1 appointment reported on 2026-05-04, each cited to the company's own filing.

Kartik Krishnan was named Chief Medical Officer of Pasithea Therapeutics Corp., effective May 1, 2026. As of November 15, 2026, Pasithea Therapeutics Corp. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 4, 2026, naming 1 appointment (Form 8-K, May 4, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Funicular Funds, LP also filed stake reports on 10 other companies ↓

Sell to companies like Pasithea Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-05-04

Pasithea Therapeutics Corp. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-04. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Pasithea Therapeutics Corp. files it.

Also on the record for Pasithea Therapeutics Corp.

DateRecordFigureOur pageSource
November 6, 2026Stake report, Schedule 13G/A, by Opaleye Management Inc.—5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by Vivo Opportunity Fund Holdings, L.P.9.99% of the class5%+ stakesSource
July 31, 2026Stake report, Schedule 13G/A, by Opaleye Management Inc.6.14% of the class5%+ stakesSource
July 1, 2026Stake report, Schedule 13G/A, by Coastlands Capital LP11.48% of the class5%+ stakesSource
June 23, 2026Stake report, Schedule 13G, by Stonepine Capital Management, LLC5.8% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Ameriprise Financial, Inc.5.4% of the class5%+ stakesSource
April 22, 2026Stake report, Schedule 13G, by Funicular Funds, LP7.4% of the class5%+ stakesSource
April 8, 2026Stake report, Schedule 13G, by Opaleye Management Inc.9.99% of the class5%+ stakesSource
February 27, 2026Stake report, Schedule 13G, by Coastlands Capital LP9.99% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G, by Ameriprise Financial, Inc.8.4% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by CVI Investments, Inc.3.8% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Squadron Master Fund LP9.9% of the class5%+ stakesSource

Selling to them or working with them? See who runs Pasithea Therapeutics Corp. now and the warning signs.

Free to see. No signup.

Keep reading

More on Pasithea Therapeutics Corp. and the records around it.

Pasithea Therapeutics Corp. elsewhere on the record

Companies that share a holder

Want the whole picture on Pasithea Therapeutics Corp.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Pasithea Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Pasithea Therapeutics Corp. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 17 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-05-04InChief Medical Officer2026-05-018-K, 2026-05-04

Who leads Pasithea Therapeutics Corp., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Pasithea Therapeutics Corp.?

New leaders reset buying decisions — get the Full Report on Pasithea Therapeutics Corp.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Pasithea Therapeutics Corp.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Medical Officer at Pasithea Therapeutics Corp., with the record behind each one.

Find candidates like Chief Medical Officer at Pasithea Therapeutics Corp.

Every change, in the filing's words

Filed 2026-05-04 · 8-K

Appointed: Kartik Krishnan, Chief Medical Officer, effective 2026-05-01

On May 4, 2026, Pasithea Therapeutics Corp. (the "Company") announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.

Also stated in this filing

  • Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform and cutaneous neurofibromas.
  • Dr. Krishnan, age 55, has over 20 years of experience in clinical development, pharmacovigilance, clinical operations, regulatory affairs, and R&D strategy.
  • Prior to joining the Company, Dr. Krishnan served as Chief Executive Officer at OncoNano Medicines, a privately held company developing anti-cancer assets.
  • Prior to that, Dr. Krishnan served as Chief Medical Officer at Arcus Biosciences, a discovery and clinical development company focusing on combination therapies in immuno-oncology.
  • Earlier in his career, Dr. Krishnan held various clinical development and medical director roles of increasing responsibility at companies including Astex Pharmaceuticals, Genentech, Five Prime Therapeutics, BioMarin, and Amgen.
  • While at Genentech, Dr. Krishnan was an integral part of the clinical team for cobimetinib (Cotellic ), contributing to its approval in the United States and Europe in 2015 for the treatment of BRAF V600E-mutant or BRAF V600K-mutant melanoma in combination with vemurafenib (Zelboraf ), and worked to establish development opportunities for this MEK inhibitor beyond melanoma.

Tools for this story

Each opens in a new tab, filled in for Pasithea Therapeutics Corp.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/pasithea-therapeutics
Last updated 2026-11-15
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Pasithea Therapeutics Corp.? (2026). MentionFox, 2026-11-15. https://mentionfox.com/executive-changes/pasithea-therapeutics